We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
<sup>90</sup>Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
- Authors
Samaniego, Felipe; Berkova, Zuzana; Romaguera, Jorge E.; Fowler, Nathan; Fanale, Michelle A.; Pro, Barbara; Shah, Jatin J.; McLaughlin, Peter; Sehgal, Lalit; Selvaraj, Vijairam; Braun, Frank K.; Mathur, Rohit; Feng, Lei; Neelapu, Sattva S.; Kwak, Larry W.
- Abstract
90Y-ibritumomab-tiuxetan (90 YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma ( FL) or marginal zone B-cell lymphoma ( MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90 YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.
- Subjects
LYMPHOMA treatment; B cell lymphoma; CANCER radioimmunotherapy; YTTRIUM; CD20 antigen; THERAPEUTIC use of monoclonal antibodies; NEUTROPENIA; THERAPEUTICS; TUMOR treatment
- Publication
British Journal of Haematology, 2014, Vol 167, Issue 2, p207
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.13021